Ozempic Poison Control Calls Nearly Doubled, and It's Almost All One Mistake
The GLP1 boom has brought millions of first time injectors into a routine that used to be mostly limited to people managing diabetes. A new poison center study puts a real number on what that transition has actually looked like, and the pattern it found is refreshingly boring in the best way: not a new drug danger, but an old fashioned instructions problem.
- A national poison center study covering 2012 through 2023 found GLP1 exposure calls involving semaglutide (Ozempic, Wegovy) jumped from about 1,000 to 1,500 a year to over 8,000 a year after the drug's 2021 weight loss approval.
- The two most common mistakes: injecting the once weekly dose every day, and skipping the gradual dose increase schedule to start right at the highest dose.
- Most cases were medically mild, and the jump tracks with far more first time injectors entering the weight loss market, not a change in the drug itself.
- Women made up 78.2% of post approval cases, versus 68.9% before, consistent with the wider, more weight loss focused user base.
The device at the centre of the dosing errors: the story is about how much comes out of one of these, and who decided.
Unsplash
Illustrative. Not a pen involved in any reported case.
What the researchers actually found
Published in the Journal of Medical Toxicology, the official journal of the American College of Medical Toxicology, the study pulled national poison center exposure data from 2012 through 2023. Before semaglutide's 2021 FDA approval for weight management, GLP1 related calls ran about 1,000 to 1,500 a year. By 2023, that number had climbed past 8,000. The clear break point lines up with the approval date, and researchers said the increase in call volume was steeper than they expected going in.
Calls per year, before and after.
Both bars are the same quantity: reported exposure calls per year. The upper bound of the pre-approval range is drawn, so the gap shown is the smallest one the data supports.
What the evidence actually shows
The two most common errors behind these calls were straightforward and preventable: people injecting their once weekly dose every day instead of once a week, and people skipping the gradual dose increase schedule to start right at the highest dose. Women made up 78.2% of post approval cases, up from 68.9% before, which lines up with semaglutide's expanded use in a broader weight loss population less familiar with injectable dosing than longtime diabetes patients. Most cases were medically mild.
- 1
- Weekly dose injected every day
- 2
- Skipped the gradual dose increase
- 78.2%
- Women, after approval
- 68.9%
- Women, before
Honest caveat
Poison center call data captures reported incidents, not every actual error, so this likely undercounts the true rate of dosing mistakes. It's associational, a before and after comparison, not a controlled study, and can't fully rule out other explanations, like rising overall GLP1 use or more media attention prompting more calls for the same rate of error. The research also began as an undergraduate data science project, though it was independently peer reviewed and published in a specialty toxicology journal, which is a real strength even given the study's limits.
What this means for you
not a new drug danger, but an old fashioned instructions problem
If you or someone you know just started an injectable GLP1 for weight loss, the two things worth confirming are simple: the dose is weekly, not daily, and the starting dose should be low, increasing gradually on the schedule your prescriber gave you, not jumping straight to the highest dose to see results faster. This isn't a reason to distrust the drug. It's a reason to slow down on day one and read the instructions the same way you would for any new medication you've never handled before.
Primary sources
- Miller, J., Miller, R., Varney, S.M., Han, D. "National Poison Center Trends in GLP1 Receptor Agonist Exposures Following FDA Approval for Weight Loss." Journal of Medical Toxicology, 2026; 22(2): 275.
- UT San Antonio press release via ScienceDaily, July 9, 2026.
Common questions
What is the single most common Ozempic dosing mistake?
Injecting the once weekly dose every day instead of once a week. The second most common mistake was skipping the gradual dose increase schedule and starting right at the highest dose, rather than titrating up slowly as prescribed.
Does this mean Ozempic or Wegovy is unsafe?
Not really. This is a patient education problem, not a new drug safety finding. Most poison control cases were medically mild, and the increase tracks with far more people, many newly injecting a GLP1 drug for the first time, not with the drug itself becoming more dangerous.
What should I do if I am new to a GLP1 injection?
Confirm with your prescriber or pharmacist that your dose is meant to be weekly, not daily, and follow the gradual titration schedule exactly as written rather than starting at a higher dose to see faster results. If you are ever unsure about a dose, call your pharmacist or poison control before injecting, not after.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.